Heterogeneous Association for Alcohol, CVD Presentation

Share this content:
Heterogeneous Association for Alcohol, CVD Presentation
Heterogeneous Association for Alcohol, CVD Presentation

THURSDAY, March 23, 2017 (HealthDay News) -- There are heterogeneous associations between the level of alcohol consumption and initial presentation of cardiovascular disease, according to a study published online March 22 in The BMJ.

Steven Bell, Ph.D., from the University of Cambridge in the United Kingdom, and colleagues examined the correlation between alcohol consumption and cardiovascular disease in a population-based cohort study of linked electronic health records. Data were included for 1,937,360 adults aged ≥30 years.

The researchers found that 114,859 individuals received an incident cardiovascular diagnosis during a median follow-up of six years. There was an association for non-drinking with increased risk of unstable angina, myocardial infarction, unheralded coronary death, heart failure, ischemic stroke, peripheral arterial disease, and abdominal aortic aneurysm (hazard ratios, 1.33, 1.32, 1.56, 1.24, 1.12, 1.22, and 1.32, respectively), compared with moderate drinking. Heavy drinking that exceeded guidelines correlated with an increased risk of presenting with unheralded coronary death, heart failure, cardiac arrest, transient ischemic attack, ischemic stroke, intracerebral hemorrhage, and peripheral arterial disease (hazard ratios, 1.21, 1.22, 1.50, 1.11, 1.33, 1.37, and 1.35, respectively), and with reduced risks of myocardial infarction (hazard ratio, 0.88; 95 percent confidence interval, 0.79 to 1.00) or stable angina (hazard ratio, 0.93; 95 percent confidence interval, 0.86 to 1.00).

"This has implications for counselling patients, public health communication, and clinical research, suggesting a more nuanced approach to the role of alcohol in prevention of cardiovascular disease is necessary," the authors write.

Abstract/Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »